Liver Fat in the Metabolic Syndrome

Background: The liver, once fatty, overproduces components of the metabolic syndrome, such as glucose and lipids. The amount of liver fat in subjects with and without the metabolic syndrome has not been determined. It is unknown which clinically available markers best reflect liver fat content. Meas...

Full description

Saved in:
Bibliographic Details
Published inThe journal of clinical endocrinology and metabolism Vol. 92; no. 9; pp. 3490 - 3497
Main Authors Kotronen, Anna, Westerbacka, Jukka, Bergholm, Robert, Pietiläinen, Kirsi H., Yki-Järvinen, Hannele
Format Journal Article
LanguageEnglish
Published Bethesda, MD Oxford University Press 01.09.2007
Endocrine Society
Subjects
Online AccessGet full text
ISSN0021-972X
1945-7197
DOI10.1210/jc.2007-0482

Cover

Abstract Background: The liver, once fatty, overproduces components of the metabolic syndrome, such as glucose and lipids. The amount of liver fat in subjects with and without the metabolic syndrome has not been determined. It is unknown which clinically available markers best reflect liver fat content. Measurements: Components of the metabolic syndrome as defined by the International Diabetes Federation and liver fat content by proton magnetic resonance spectroscopy were measured in 271 nondiabetic subjects (162 women, 109 men). In addition, other features of insulin resistance (serum insulin, C-peptide), intraabdominal and sc fat by magnetic resonance imaging, and liver enzymes (serum alanine aminotransferase and serum aspartate aminotransferase) were measured. Results: Liver fat was 4-fold higher in subjects with [n = 116; median 8.2% (interquartile range 3.2–18.7%)] than without [n = 155; 2.0% (1.0–5.0%); P < 0.0001] the metabolic syndrome. This increase in liver fat remained significant after adjusting for age, gender, and body mass index. All components of the metabolic syndrome correlated with liver fat content. The best correlate was waist in both women (r = 0.59, P < 0.0001) and men (r = 0.56, P < 0.0001). Liver fat correlated significantly with serum alanine aminotransferase (r = 0.39, P < 0.0001 for women; r = 0.44, P < 0.0001 for men) and aspartate aminotransferase (r = 0.27, P = 0.0005 for women; r = 0.31, P = 0.0012 for men) concentrations. The best correlates of liver fat were fasting serum insulin (r = 0.61; P < 0.0001 for both women and men) and C-peptide (r = 0.62; P < 0.0001 for both women and men). Conclusions: Liver fat content is significantly increased in subjects with the metabolic syndrome as compared with those without the syndrome, independently of age, gender, and body mass index. Of other markers, serum C-peptide is the strongest correlate of liver fat.
AbstractList The liver, once fatty, overproduces components of the metabolic syndrome, such as glucose and lipids. The amount of liver fat in subjects with and without the metabolic syndrome has not been determined. It is unknown which clinically available markers best reflect liver fat content. Components of the metabolic syndrome as defined by the International Diabetes Federation and liver fat content by proton magnetic resonance spectroscopy were measured in 271 nondiabetic subjects (162 women, 109 men). In addition, other features of insulin resistance (serum insulin, C-peptide), intraabdominal and sc fat by magnetic resonance imaging, and liver enzymes (serum alanine aminotransferase and serum aspartate aminotransferase) were measured. Liver fat was 4-fold higher in subjects with [n = 116; median 8.2% (interquartile range 3.2-18.7%)] than without [n = 155; 2.0% (1.0-5.0%); P < 0.0001] the metabolic syndrome. This increase in liver fat remained significant after adjusting for age, gender, and body mass index. All components of the metabolic syndrome correlated with liver fat content. The best correlate was waist in both women (r = 0.59, P < 0.0001) and men (r = 0.56, P < 0.0001). Liver fat correlated significantly with serum alanine aminotransferase (r = 0.39, P < 0.0001 for women; r = 0.44, P < 0.0001 for men) and aspartate aminotransferase (r = 0.27, P = 0.0005 for women; r = 0.31, P = 0.0012 for men) concentrations. The best correlates of liver fat were fasting serum insulin (r = 0.61; P < 0.0001 for both women and men) and C-peptide (r = 0.62; P < 0.0001 for both women and men). Liver fat content is significantly increased in subjects with the metabolic syndrome as compared with those without the syndrome, independently of age, gender, and body mass index. Of other markers, serum C-peptide is the strongest correlate of liver fat.
The liver, once fatty, overproduces components of the metabolic syndrome, such as glucose and lipids. The amount of liver fat in subjects with and without the metabolic syndrome has not been determined. It is unknown which clinically available markers best reflect liver fat content.BACKGROUNDThe liver, once fatty, overproduces components of the metabolic syndrome, such as glucose and lipids. The amount of liver fat in subjects with and without the metabolic syndrome has not been determined. It is unknown which clinically available markers best reflect liver fat content.Components of the metabolic syndrome as defined by the International Diabetes Federation and liver fat content by proton magnetic resonance spectroscopy were measured in 271 nondiabetic subjects (162 women, 109 men). In addition, other features of insulin resistance (serum insulin, C-peptide), intraabdominal and sc fat by magnetic resonance imaging, and liver enzymes (serum alanine aminotransferase and serum aspartate aminotransferase) were measured.MEASUREMENTSComponents of the metabolic syndrome as defined by the International Diabetes Federation and liver fat content by proton magnetic resonance spectroscopy were measured in 271 nondiabetic subjects (162 women, 109 men). In addition, other features of insulin resistance (serum insulin, C-peptide), intraabdominal and sc fat by magnetic resonance imaging, and liver enzymes (serum alanine aminotransferase and serum aspartate aminotransferase) were measured.Liver fat was 4-fold higher in subjects with [n = 116; median 8.2% (interquartile range 3.2-18.7%)] than without [n = 155; 2.0% (1.0-5.0%); P < 0.0001] the metabolic syndrome. This increase in liver fat remained significant after adjusting for age, gender, and body mass index. All components of the metabolic syndrome correlated with liver fat content. The best correlate was waist in both women (r = 0.59, P < 0.0001) and men (r = 0.56, P < 0.0001). Liver fat correlated significantly with serum alanine aminotransferase (r = 0.39, P < 0.0001 for women; r = 0.44, P < 0.0001 for men) and aspartate aminotransferase (r = 0.27, P = 0.0005 for women; r = 0.31, P = 0.0012 for men) concentrations. The best correlates of liver fat were fasting serum insulin (r = 0.61; P < 0.0001 for both women and men) and C-peptide (r = 0.62; P < 0.0001 for both women and men).RESULTSLiver fat was 4-fold higher in subjects with [n = 116; median 8.2% (interquartile range 3.2-18.7%)] than without [n = 155; 2.0% (1.0-5.0%); P < 0.0001] the metabolic syndrome. This increase in liver fat remained significant after adjusting for age, gender, and body mass index. All components of the metabolic syndrome correlated with liver fat content. The best correlate was waist in both women (r = 0.59, P < 0.0001) and men (r = 0.56, P < 0.0001). Liver fat correlated significantly with serum alanine aminotransferase (r = 0.39, P < 0.0001 for women; r = 0.44, P < 0.0001 for men) and aspartate aminotransferase (r = 0.27, P = 0.0005 for women; r = 0.31, P = 0.0012 for men) concentrations. The best correlates of liver fat were fasting serum insulin (r = 0.61; P < 0.0001 for both women and men) and C-peptide (r = 0.62; P < 0.0001 for both women and men).Liver fat content is significantly increased in subjects with the metabolic syndrome as compared with those without the syndrome, independently of age, gender, and body mass index. Of other markers, serum C-peptide is the strongest correlate of liver fat.CONCLUSIONSLiver fat content is significantly increased in subjects with the metabolic syndrome as compared with those without the syndrome, independently of age, gender, and body mass index. Of other markers, serum C-peptide is the strongest correlate of liver fat.
Background: The liver, once fatty, overproduces components of the metabolic syndrome, such as glucose and lipids. The amount of liver fat in subjects with and without the metabolic syndrome has not been determined. It is unknown which clinically available markers best reflect liver fat content. Measurements: Components of the metabolic syndrome as defined by the International Diabetes Federation and liver fat content by proton magnetic resonance spectroscopy were measured in 271 nondiabetic subjects (162 women, 109 men). In addition, other features of insulin resistance (serum insulin, C-peptide), intraabdominal and sc fat by magnetic resonance imaging, and liver enzymes (serum alanine aminotransferase and serum aspartate aminotransferase) were measured. Results: Liver fat was 4-fold higher in subjects with [n = 116; median 8.2% (interquartile range 3.2–18.7%)] than without [n = 155; 2.0% (1.0–5.0%); P < 0.0001] the metabolic syndrome. This increase in liver fat remained significant after adjusting for age, gender, and body mass index. All components of the metabolic syndrome correlated with liver fat content. The best correlate was waist in both women (r = 0.59, P < 0.0001) and men (r = 0.56, P < 0.0001). Liver fat correlated significantly with serum alanine aminotransferase (r = 0.39, P < 0.0001 for women; r = 0.44, P < 0.0001 for men) and aspartate aminotransferase (r = 0.27, P = 0.0005 for women; r = 0.31, P = 0.0012 for men) concentrations. The best correlates of liver fat were fasting serum insulin (r = 0.61; P < 0.0001 for both women and men) and C-peptide (r = 0.62; P < 0.0001 for both women and men). Conclusions: Liver fat content is significantly increased in subjects with the metabolic syndrome as compared with those without the syndrome, independently of age, gender, and body mass index. Of other markers, serum C-peptide is the strongest correlate of liver fat.
Background: The liver, once fatty, overproduces components of the metabolic syndrome, such as glucose and lipids. The amount of liver fat in subjects with and without the metabolic syndrome has not been determined. It is unknown which clinically available markers best reflect liver fat content. Measurements: Components of the metabolic syndrome as defined by the International Diabetes Federation and liver fat content by proton magnetic resonance spectroscopy were measured in 271 nondiabetic subjects (162 women, 109 men). In addition, other features of insulin resistance (serum insulin, C-peptide), intraabdominal and sc fat by magnetic resonance imaging, and liver enzymes (serum alanine aminotransferase and serum aspartate aminotransferase) were measured. Results: Liver fat was 4-fold higher in subjects with [n = 116; median 8.2% (interquartile range 3.2–18.7%)] than without [n = 155; 2.0% (1.0–5.0%); P < 0.0001] the metabolic syndrome. This increase in liver fat remained significant after adjusting for age, gender, and body mass index. All components of the metabolic syndrome correlated with liver fat content. The best correlate was waist in both women (r = 0.59, P < 0.0001) and men (r = 0.56, P < 0.0001). Liver fat correlated significantly with serum alanine aminotransferase (r = 0.39, P < 0.0001 for women; r = 0.44, P < 0.0001 for men) and aspartate aminotransferase (r = 0.27, P = 0.0005 for women; r = 0.31, P = 0.0012 for men) concentrations. The best correlates of liver fat were fasting serum insulin (r = 0.61; P < 0.0001 for both women and men) and C-peptide (r = 0.62; P < 0.0001 for both women and men). Conclusions: Liver fat content is significantly increased in subjects with the metabolic syndrome as compared with those without the syndrome, independently of age, gender, and body mass index. Of other markers, serum C-peptide is the strongest correlate of liver fat.
Author Yki-Järvinen, Hannele
Westerbacka, Jukka
Bergholm, Robert
Pietiläinen, Kirsi H.
Kotronen, Anna
Author_xml – sequence: 1
  givenname: Anna
  surname: Kotronen
  fullname: Kotronen, Anna
  organization: 1 Department of Medicine (A.K., J.W., R.B., K.H.P., H.Y.-J.), Department of Psychiatry, University of Helsinki, FIN-00029 Helsinki, Finland
– sequence: 2
  givenname: Jukka
  surname: Westerbacka
  fullname: Westerbacka, Jukka
  organization: 1 Department of Medicine (A.K., J.W., R.B., K.H.P., H.Y.-J.), Department of Psychiatry, University of Helsinki, FIN-00029 Helsinki, Finland
– sequence: 3
  givenname: Robert
  surname: Bergholm
  fullname: Bergholm, Robert
  organization: 1 Department of Medicine (A.K., J.W., R.B., K.H.P., H.Y.-J.), Department of Psychiatry, University of Helsinki, FIN-00029 Helsinki, Finland
– sequence: 4
  givenname: Kirsi H.
  surname: Pietiläinen
  fullname: Pietiläinen, Kirsi H.
  organization: 1 Department of Medicine (A.K., J.W., R.B., K.H.P., H.Y.-J.), Department of Psychiatry, University of Helsinki, FIN-00029 Helsinki, Finland
– sequence: 5
  givenname: Hannele
  surname: Yki-Järvinen
  fullname: Yki-Järvinen, Hannele
  email: ykijarvi@cc.helsinki.fi
  organization: 1 Department of Medicine (A.K., J.W., R.B., K.H.P., H.Y.-J.), Department of Psychiatry, University of Helsinki, FIN-00029 Helsinki, Finland
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=19081800$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/17595248$$D View this record in MEDLINE/PubMed
BookMark eNp10U1LAzEQBuAgFVs_bp5loagXVyfZbD6OIlaFigcVvIVsNosp201NdoX-e7e2Kogehrk8M8zw7qJB4xuL0CGGc0wwXMzMOQHgKVBBttAIS5qnHEs-QCMAglPJycsQ7cY4A8CU5tkOGmKey5xQMULjqXu3IZnoNnFN0r7a5N62uvC1M8njsimDn9t9tF3pOtqDTd9Dz5Prp6vbdPpwc3d1OU1NxmWbcqCMVQBGaEnB5ERKKrVmJUButc5KUghSMGYlEaSklmNeVBiIpqwgDFfZHjpZ710E_9bZ2Kq5i8bWtW6s76JiglCWg-jh-Bec-S40_W0qw4zSvoD06mijumJuS7UIbq7DUn0934PjDdDR6LoKujEu_jgJAguA3pG1M8HHGGyljGt163zTBu1qhUGtklAzo1ZJqFUS_dDZr6HvvX_z0zX33eI_-Rlx9gFMsZCp
CODEN JCEMAZ
CitedBy_id crossref_primary_10_1016_j_jhep_2009_02_031
crossref_primary_10_3390_nu14030716
crossref_primary_10_1080_14728222_2020_1728742
crossref_primary_10_1161_CIR_0b013e318233bc6a
crossref_primary_10_1016_j_trsl_2017_10_009
crossref_primary_10_1093_cid_ciz435
crossref_primary_10_1097_MCO_0b013e32833ec41b
crossref_primary_10_3390_ijms24021090
crossref_primary_10_1038_nrgastro_2016_147
crossref_primary_10_1016_j_nutres_2012_06_012
crossref_primary_10_2337_dc07_1463
crossref_primary_10_1186_s12887_015_0378_8
crossref_primary_10_1111_apha_12253
crossref_primary_10_1002_nbm_2837
crossref_primary_10_1002_oby_20114
crossref_primary_10_1002_hep_32519
crossref_primary_10_1111_apt_14499
crossref_primary_10_1016_j_jbc_2021_100714
crossref_primary_10_3390_genes11111243
crossref_primary_10_1016_j_dld_2015_08_004
crossref_primary_10_1016_j_jhepr_2021_100322
crossref_primary_10_1016_j_expneurol_2021_113725
crossref_primary_10_3390_nu15234870
crossref_primary_10_1017_S0029665121003761
crossref_primary_10_1002_hep4_1070
crossref_primary_10_1016_j_mam_2016_11_008
crossref_primary_10_1007_s11883_022_00996_x
crossref_primary_10_3389_fphar_2022_910789
crossref_primary_10_14218_JCTH_2019_00030
crossref_primary_10_1016_S2213_8587_14_70032_4
crossref_primary_10_5812_hepatmon_35055
crossref_primary_10_3390_ijms22126642
crossref_primary_10_3350_cmh_2021_0371
crossref_primary_10_3390_ijms17050633
crossref_primary_10_1155_2021_6620289
crossref_primary_10_23736_S2724_5985_22_03139_4
crossref_primary_10_1093_ajcn_88_1_16
crossref_primary_10_1038_bmt_2010_144
crossref_primary_10_1089_met_2017_0058
crossref_primary_10_1210_en_2012_1390
crossref_primary_10_3748_wjg_14_3476
crossref_primary_10_1016_j_jhep_2009_05_023
crossref_primary_10_1136_postgradmedj_2013_201620rep
crossref_primary_10_1016_j_clinre_2014_08_014
crossref_primary_10_1016_j_jhep_2016_09_022
crossref_primary_10_3945_ajcn_112_038695
crossref_primary_10_1016_j_exger_2013_05_059
crossref_primary_10_1186_1471_2458_10_237
crossref_primary_10_1016_j_diabet_2018_11_003
crossref_primary_10_1016_j_jhep_2008_12_025
crossref_primary_10_1515_CCLM_2010_302
crossref_primary_10_2196_17110
crossref_primary_10_1093_eurheartj_ehr453
crossref_primary_10_1177_1756283X11405251
crossref_primary_10_1016_S1665_2681_19_31484_X
crossref_primary_10_1097_MD_0000000000040417
crossref_primary_10_1210_clinem_dgaf094
crossref_primary_10_1016_j_ijcard_2013_06_024
crossref_primary_10_1186_s12902_021_00758_x
crossref_primary_10_3109_07853890_2010_532152
crossref_primary_10_1586_eem_10_5
crossref_primary_10_3390_jcm10030390
crossref_primary_10_1016_j_ctim_2024_103018
crossref_primary_10_1111_j_1440_1746_2010_06509_x
crossref_primary_10_1016_j_diabres_2024_111609
crossref_primary_10_1007_s00125_013_2829_9
crossref_primary_10_1007_s11377_016_0063_y
crossref_primary_10_3390_nu11122871
crossref_primary_10_4103_jod_jod_17_21
crossref_primary_10_1111_j_1365_2893_2010_01394_x
crossref_primary_10_3390_biomedicines11061595
crossref_primary_10_1038_oby_2010_291
crossref_primary_10_1152_ajpendo_00272_2010
crossref_primary_10_1136_bmj_m4747
crossref_primary_10_1007_s13340_020_00448_4
crossref_primary_10_1016_j_cmet_2011_06_007
crossref_primary_10_1155_2015_535982
crossref_primary_10_1186_1475_2840_9_30
crossref_primary_10_1007_s11901_016_0295_9
crossref_primary_10_1038_s41598_017_13209_2
crossref_primary_10_1210_jc_2017_02751
crossref_primary_10_1177_0003319715576672
crossref_primary_10_1016_j_jnutbio_2015_12_005
crossref_primary_10_2478_v10255_012_0019_z
crossref_primary_10_1530_EJE_16_0608
crossref_primary_10_1371_journal_pone_0221524
crossref_primary_10_3390_ijms17091554
crossref_primary_10_1016_j_expneurol_2018_04_004
crossref_primary_10_1530_EJE_10_0186
crossref_primary_10_3389_fendo_2022_866189
crossref_primary_10_1016_j_numecd_2008_12_007
crossref_primary_10_1111_eci_13878
crossref_primary_10_1111_j_1365_2036_2008_03896_x
crossref_primary_10_1016_j_livres_2022_05_005
crossref_primary_10_1039_c2mb25115a
crossref_primary_10_5812_hepatmon_37388
crossref_primary_10_1155_2016_5251738
crossref_primary_10_3892_etm_2013_1090
crossref_primary_10_1136_jclinpath_2013_201620
crossref_primary_10_1016_j_hfc_2012_06_010
crossref_primary_10_1160_TH13_06_0499
crossref_primary_10_17352_ahr_000004
crossref_primary_10_1177_1756283X11403809
crossref_primary_10_1038_s41598_017_14706_0
crossref_primary_10_1136_bmjgast_2021_000817
crossref_primary_10_1155_2012_716404
crossref_primary_10_1016_j_jhep_2010_04_008
crossref_primary_10_1007_s00246_012_0447_9
crossref_primary_10_1016_j_fct_2012_04_039
crossref_primary_10_1111_j_1478_3231_2011_02526_x
crossref_primary_10_1080_13697130802447074
crossref_primary_10_7861_clinmedicine_15_6_s77
crossref_primary_10_18553_jmcp_2020_26_6_775
crossref_primary_10_1111_cen_12758
crossref_primary_10_14814_phy2_12661
crossref_primary_10_1053_j_gastro_2008_03_021
crossref_primary_10_1007_s11695_023_07014_2
crossref_primary_10_1155_2021_6696473
crossref_primary_10_1177_21501319241247974
crossref_primary_10_1007_s10620_013_2957_6
crossref_primary_10_3390_biomedicines11030663
crossref_primary_10_1053_j_gastro_2010_06_064
crossref_primary_10_1016_j_ijcard_2013_07_230
crossref_primary_10_1038_nrgastro_2010_41
crossref_primary_10_1002_hep_26342
crossref_primary_10_3851_IMP2039
crossref_primary_10_3390_jcm11051375
crossref_primary_10_1152_ajpendo_00444_2007
crossref_primary_10_1002_oby_22432
crossref_primary_10_1097_MCO_0b013e32833f4b34
crossref_primary_10_2147_DMSO_S314935
crossref_primary_10_1017_S0007114510002187
crossref_primary_10_1016_j_dld_2014_09_020
crossref_primary_10_1093_bja_aev199
crossref_primary_10_1097_CRD_0000000000000537
crossref_primary_10_1016_j_nutres_2013_09_002
crossref_primary_10_1586_17474124_2015_1056156
crossref_primary_10_14218_JCTH_2019_00010
crossref_primary_10_1016_j_hbpd_2021_06_002
crossref_primary_10_2478_inmed_2019_0052
crossref_primary_10_1007_s00125_008_1135_4
crossref_primary_10_1161_ATVBAHA_112_300075
crossref_primary_10_3390_antiox10101546
crossref_primary_10_1016_j_jhep_2010_05_037
crossref_primary_10_1210_jc_2007_1825
crossref_primary_10_1111_jdi_12107
crossref_primary_10_1186_1741_7015_9_85
crossref_primary_10_1016_j_bbadis_2018_09_013
crossref_primary_10_1016_j_metabol_2016_06_009
crossref_primary_10_3390_nu7115454
crossref_primary_10_1210_jc_2008_1245
crossref_primary_10_1016_j_atherosclerosis_2015_07_018
crossref_primary_10_1016_j_cgh_2008_11_023
crossref_primary_10_1016_S1262_3636_08_74600_7
crossref_primary_10_1038_oby_2010_137
crossref_primary_10_1016_j_cca_2008_07_024
crossref_primary_10_7759_cureus_41959
crossref_primary_10_1007_s11695_023_06804_y
crossref_primary_10_17656_jsmc_10094
crossref_primary_10_1152_ajpgi_00074_2008
crossref_primary_10_4166_kjg_2013_62_6_344
crossref_primary_10_1038_ejcn_2010_27
crossref_primary_10_2217_clp_12_47
crossref_primary_10_3390_nu14173452
crossref_primary_10_3390_ijms21165888
crossref_primary_10_1016_j_jhep_2010_07_029
crossref_primary_10_1016_j_bbalip_2015_12_019
crossref_primary_10_1089_met_2012_0169
crossref_primary_10_1038_ijo_2010_40
crossref_primary_10_1111_joim_20032
crossref_primary_10_4162_nrp_2017_11_2_105
crossref_primary_10_1038_ijo_2012_181
crossref_primary_10_1210_jc_2017_00867
crossref_primary_10_1515_HMBCI_2010_002
crossref_primary_10_1016_j_physbeh_2007_11_049
crossref_primary_10_1017_S0029665118002653
crossref_primary_10_1371_journal_pone_0032213
crossref_primary_10_2217_clp_11_68
crossref_primary_10_1016_j_dld_2010_01_016
crossref_primary_10_1002_dmrr_2888
crossref_primary_10_1007_s40267_013_0043_y
crossref_primary_10_1186_s13098_019_0408_z
crossref_primary_10_1038_oby_2011_152
crossref_primary_10_1136_gutjnl_2017_313884
crossref_primary_10_17826_cumj_407589
crossref_primary_10_37349_emed_2020_00019
crossref_primary_10_5812_hepatmon_33155
crossref_primary_10_1007_s12072_013_9430_7
crossref_primary_10_1007_s13258_023_01391_9
crossref_primary_10_1016_j_diabres_2020_108027
crossref_primary_10_1038_s41598_021_84577_z
crossref_primary_10_1038_oby_2010_236
crossref_primary_10_1186_s12967_015_0762_z
crossref_primary_10_1148_radiol_12110772
crossref_primary_10_1097_HJH_0b013e32830dfe4b
crossref_primary_10_2337_dc11_s224
crossref_primary_10_1016_j_ddmec_2010_05_002
crossref_primary_10_1016_j_physbeh_2008_05_024
crossref_primary_10_1111_j_1440_1746_2011_07045_x
crossref_primary_10_3390_ijms222011128
crossref_primary_10_1016_j_clinre_2021_101769
crossref_primary_10_1038_nrendo_2011_138
crossref_primary_10_1002_hep_22220
crossref_primary_10_1016_j_jhep_2013_05_044
crossref_primary_10_1155_2012_914938
crossref_primary_10_1161_CIRCULATIONAHA_111_067264
crossref_primary_10_1155_2020_9519625
crossref_primary_10_1371_journal_pone_0062561
crossref_primary_10_1016_j_clinre_2024_102461
crossref_primary_10_1139_cjpp_2019_0037
crossref_primary_10_1016_j_rvsc_2009_12_012
crossref_primary_10_1016_S1665_2681_19_31850_2
crossref_primary_10_1016_j_jhep_2017_12_001
crossref_primary_10_1111_cen_12105
crossref_primary_10_1021_acs_jafc_2c05676
crossref_primary_10_1155_2017_3912567
crossref_primary_10_1530_JOE_11_0406
crossref_primary_10_1038_nutd_2011_2
crossref_primary_10_5812_hepatmon_26818
crossref_primary_10_1007_s00125_016_3944_1
crossref_primary_10_1007_s11695_009_9806_x
crossref_primary_10_1136_pgmj_2008_078014
crossref_primary_10_1007_s00535_012_0585_0
crossref_primary_10_1194_jlr_M046607
crossref_primary_10_18632_oncotarget_10915
crossref_primary_10_1007_s00125_009_1285_z
crossref_primary_10_1111_jdi_12418
crossref_primary_10_1194_jlr_P054387
crossref_primary_10_1210_jc_2012_2081
crossref_primary_10_1111_liv_14650
crossref_primary_10_1111_j_1365_2362_2010_02372_x
crossref_primary_10_1530_EC_18_0497
crossref_primary_10_1186_s12944_017_0537_z
crossref_primary_10_2337_db18_0539
crossref_primary_10_4093_dmj_2020_0137
crossref_primary_10_1016_j_cbi_2014_05_003
crossref_primary_10_1038_oby_2010_86
crossref_primary_10_1097_MOL_0b013e328317cc42
crossref_primary_10_1186_s12967_015_0684_9
crossref_primary_10_1007_s10072_014_1798_1
crossref_primary_10_1097_MOL_0b013e328338ca61
crossref_primary_10_2147_CIA_S301741
crossref_primary_10_1007_s13410_022_01097_w
crossref_primary_10_1590_0102_311xen090522
crossref_primary_10_1016_j_pnmrs_2013_04_001
crossref_primary_10_1016_j_jpsychores_2022_110785
crossref_primary_10_1111_jdi_12731
crossref_primary_10_1016_j_vph_2015_04_004
crossref_primary_10_1007_s00404_020_05696_y
crossref_primary_10_5124_jkma_2012_55_10_1005
crossref_primary_10_1007_s40265_012_0004_0
crossref_primary_10_3390_metabo13070822
crossref_primary_10_1016_j_advnut_2023_08_005
crossref_primary_10_1016_j_jhep_2010_06_013
crossref_primary_10_1111_scs_12029
crossref_primary_10_3390_metabo12050431
crossref_primary_10_7570_jomes22021
crossref_primary_10_1007_s12170_014_0384_7
crossref_primary_10_1016_j_beem_2016_06_006
crossref_primary_10_1016_j_cca_2018_10_033
crossref_primary_10_1111_j_1464_5491_2009_02785_x
crossref_primary_10_1016_j_ijsu_2014_12_028
crossref_primary_10_1186_s12882_024_03757_x
crossref_primary_10_1371_journal_pone_0009997
crossref_primary_10_3748_wjg_v20_i28_9330
crossref_primary_10_1111_ijpo_232
crossref_primary_10_1210_er_2008_0024
crossref_primary_10_1016_j_numecd_2011_04_010
crossref_primary_10_1016_j_jceh_2018_06_011
crossref_primary_10_3390_ijms20010006
crossref_primary_10_1016_j_atherosclerosis_2011_03_013
crossref_primary_10_3350_cmh_2021_0178
crossref_primary_10_1016_j_cgh_2015_05_001
crossref_primary_10_1055_a_1491_5792
crossref_primary_10_1111_j_1478_3231_2008_01952_x
crossref_primary_10_1016_j_dld_2017_08_030
crossref_primary_10_1007_s00394_015_1129_1
crossref_primary_10_1530_EJE_08_0900
crossref_primary_10_3109_01913123_2014_947010
crossref_primary_10_1055_a_1862_9088
crossref_primary_10_1161_JAHA_115_002258
crossref_primary_10_3350_cmh_2018_0037
crossref_primary_10_1042_CS20070311
crossref_primary_10_1097_MOL_0b013e3282f41b4f
crossref_primary_10_1038_s41598_017_15232_9
crossref_primary_10_1517_14656566_2011_629188
crossref_primary_10_1002_hep_26183
crossref_primary_10_1016_j_clnu_2011_01_006
crossref_primary_10_1152_physrev_00033_2011
crossref_primary_10_1371_journal_pone_0160704
crossref_primary_10_1186_s40064_015_1049_9
crossref_primary_10_1016_j_cld_2013_09_014
crossref_primary_10_1007_s11427_015_4836_1
crossref_primary_10_1007_BF03165969
crossref_primary_10_1111_j_1365_2362_2011_02572_x
crossref_primary_10_1038_pr_2016_3
crossref_primary_10_1038_srep15256
crossref_primary_10_1053_j_gastro_2009_06_005
crossref_primary_10_4158_EP12331_OR
crossref_primary_10_1371_journal_pone_0127368
crossref_primary_10_1111_j_1751_2980_2008_00323_x
crossref_primary_10_1038_nrgastro_2013_41
crossref_primary_10_3748_wjg_v22_i2_681
crossref_primary_10_1007_s11892_011_0190_2
crossref_primary_10_1007_s00125_009_1282_2
crossref_primary_10_11005_jbm_2017_24_4_223
crossref_primary_10_1152_ajpendo_90224_2008
crossref_primary_10_1210_er_2008_0009
crossref_primary_10_1161_JAHA_113_000297
crossref_primary_10_1007_s00330_023_10081_9
crossref_primary_10_1097_MOL_0b013e32831b7581
crossref_primary_10_14814_phy2_13386
crossref_primary_10_3389_fmed_2019_00202
crossref_primary_10_1002_hep_22940
crossref_primary_10_1016_j_ajcnut_2024_06_006
crossref_primary_10_1038_nrgastro_2017_109
crossref_primary_10_15171_mejdd_2017_56
Cites_doi 10.2337/diabetes.49.5.749
10.7326/0003-4819-132-2-200001180-00004
10.1161/01.ATV.0000148324.63685.6a
10.1016/S1043-2760(03)00078-X
10.2337/diab.26.1.22
10.1007/s00125-005-0125-z
10.1016/S0021-9673(01)89052-X
10.1093/ajcn/41.4.810
10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S
10.1101/gad.12.20.3168
10.1152/ajpendo.00117.2003
10.1046/j.1440-1746.2002.02846.x
10.1038/sj.ijo.0803189
10.1161/01.CIR.0000055014.62083.05
10.1152/ajpendo.00381.2004
10.3168/jds.S0022-0302(98)75630-9
10.2337/diabetes.53.8.2169
10.1080/07853890510037383
10.7326/0003-4819-137-1-200207020-00006
10.1111/j.1365-2265.2006.02543.x
10.1152/ajpendo.00064.2004
10.1016/S0140-6736(78)91595-7
10.1097/00002030-200211080-00011
10.1161/01.ATV.0000062885.61917.A5
10.1136/jech.45.2.131
10.1210/jc.2004-2479
10.1038/oby.2002.118
10.1016/S0022-2275(20)38029-9
10.1016/0730-725X(94)92543-7
10.1002/hep.20149
10.7326/0003-4819-143-10-200511150-00009
10.2337/diab.33.5.486
10.1210/jcem.87.7.8638
10.1172/JCI21047
10.1007/s00125-004-1460-1
10.1093/clinchem/18.6.499
10.1093/clinchem/14.2.116
ContentType Journal Article
Copyright Copyright © 2007 by The Endocrine Society 2007
2007 INIST-CNRS
Copyright © 2007 by The Endocrine Society
Copyright_xml – notice: Copyright © 2007 by The Endocrine Society 2007
– notice: 2007 INIST-CNRS
– notice: Copyright © 2007 by The Endocrine Society
DBID AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7QP
7T5
7TM
H94
K9.
7X8
DOI 10.1210/jc.2007-0482
DatabaseName CrossRef
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Calcium & Calcified Tissue Abstracts
Immunology Abstracts
Nucleic Acids Abstracts
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Immunology Abstracts
Calcium & Calcified Tissue Abstracts
Nucleic Acids Abstracts
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic

AIDS and Cancer Research Abstracts
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1945-7197
EndPage 3497
ExternalDocumentID 17595248
19081800
10_1210_jc_2007_0482
10.1210/jc.2007-0482
Genre Research Support, Non-U.S. Gov't
Journal Article
Comparative Study
GroupedDBID ---
-~X
.55
.XZ
08P
0R~
18M
1TH
2WC
34G
354
39C
4.4
48X
53G
5GY
5RS
5YH
8F7
AABZA
AACZT
AAIMJ
AAPQZ
AAPXW
AARHZ
AAUAY
AAVAP
AAWTL
ABBLC
ABDFA
ABEJV
ABGNP
ABJNI
ABLJU
ABMNT
ABNHQ
ABOCM
ABPMR
ABPPZ
ABPQP
ABPTD
ABQNK
ABVGC
ABWST
ABXVV
ACGFO
ACGFS
ACPRK
ACUTJ
ACYHN
ADBBV
ADGKP
ADGZP
ADHKW
ADQBN
ADRTK
ADVEK
AELWJ
AEMDU
AENEX
AENZO
AERZD
AETBJ
AEWNT
AFCHL
AFFNX
AFFZL
AFGWE
AFOFC
AFRAH
AFXAL
AGINJ
AGKRT
AGQXC
AGUTN
AHMBA
AHMMS
AJEEA
ALMA_UNASSIGNED_HOLDINGS
APIBT
ARIXL
ASPBG
ATGXG
AVWKF
AZFZN
BAWUL
BAYMD
BCRHZ
BEYMZ
BSWAC
BTRTY
C45
CDBKE
CS3
DAKXR
DIK
E3Z
EBS
EJD
EMOBN
ENERS
F5P
FECEO
FHSFR
FLUFQ
FOEOM
FOTVD
FQBLK
GAUVT
GJXCC
GX1
H13
HZ~
H~9
J5H
KBUDW
KOP
KQ8
KSI
KSN
L7B
M5~
MHKGH
MJL
N4W
N9A
NLBLG
NOMLY
NOYVH
NVLIB
O9-
OAUYM
OBH
OCB
ODMLO
OFXIZ
OGEVE
OHH
OJZSN
OK1
OPAEJ
OVD
OVIDX
P2P
P6G
REU
ROX
ROZ
TEORI
TJX
TLC
TR2
TWZ
VVN
W8F
WOQ
X7M
YBU
YFH
YHG
YOC
YSK
ZY1
~02
~H1
AAYXX
ABXZS
ADNBA
AEHZK
AEMQT
AEOTA
AFYAG
ALXQX
CITATION
NU-
.GJ
29K
3O-
7X7
88E
8FI
8FJ
AAJQQ
AAKAS
AAPGJ
AAQQT
AAUQX
AAWDT
AAYJJ
ABDPE
ABUWG
ACFRR
ACVCV
ACZBC
ADMTO
ADZCM
AFFQV
AFKRA
AGMDO
AGORE
AHGBF
AI.
AJBYB
AJDVS
APJGH
AQDSO
AQKUS
AVNTJ
BENPR
BPHCQ
BVXVI
CCPQU
D-I
EIHJH
FEDTE
FYUFA
HMCUK
HVGLF
IAO
IHR
INH
IQODW
ITC
M1P
MBLQV
OBFPC
PHGZM
PHGZT
PJZUB
PPXIY
PQQKQ
PROAC
PSQYO
TMA
UKHRP
VH1
WHG
X52
ZGI
ZXP
3V.
CGR
CUY
CVF
ECM
EIF
NPM
VXZ
7QP
7T5
7TM
H94
K9.
7X8
ID FETCH-LOGICAL-c379t-70466f00c8a940c529949aa6d005eaa3d2b82b66e9282d4e717bf102a46b261f3
ISSN 0021-972X
IngestDate Mon Sep 08 13:57:51 EDT 2025
Fri Sep 19 20:52:16 EDT 2025
Wed Feb 19 01:40:54 EST 2025
Mon Jul 21 09:13:52 EDT 2025
Thu Apr 24 23:03:39 EDT 2025
Wed Oct 01 04:41:30 EDT 2025
Fri Feb 07 10:35:43 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 9
Keywords Endocrinopathy
Obesity
Nutrition
Digestive system
X Syndrome
Liver
Nutrition disorder
Fat
Cardiovascular disease
Metabolic diseases
Endocrinology
Nutritional status
Language English
License CC BY 4.0
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c379t-70466f00c8a940c529949aa6d005eaa3d2b82b66e9282d4e717bf102a46b261f3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Article-2
ObjectType-Feature-1
content type line 23
PMID 17595248
PQID 3164416402
PQPubID 2046206
PageCount 8
ParticipantIDs proquest_miscellaneous_68246508
proquest_journals_3164416402
pubmed_primary_17595248
pascalfrancis_primary_19081800
crossref_citationtrail_10_1210_jc_2007_0482
crossref_primary_10_1210_jc_2007_0482
oup_primary_10_1210_jc_2007-0482
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2007-09-01
PublicationDateYYYYMMDD 2007-09-01
PublicationDate_xml – month: 09
  year: 2007
  text: 2007-09-01
  day: 01
PublicationDecade 2000
PublicationPlace Bethesda, MD
PublicationPlace_xml – name: Bethesda, MD
– name: United States
– name: Washington
PublicationTitle The journal of clinical endocrinology and metabolism
PublicationTitleAlternate J Clin Endocrinol Metab
PublicationYear 2007
Publisher Oxford University Press
Endocrine Society
Publisher_xml – name: Oxford University Press
– name: Endocrine Society
References Hamaguchi ( key 2019041113575174100_R15) 2005; 143
Alberti ( key 2019041113575174100_R1) 2005
Yki-Jarvinen ( key 2019041113575174100_R2) 2005; 37
Lehti ( key 2019041113575174100_R35) 1971
Stranges ( key 2019041113575174100_R37) 2004; 39
Kuzuya ( key 2019041113575174100_R25) 1977; 26
Tiikkainen ( key 2019041113575174100_R10) 2002; 10
Nikkila ( key 2019041113575174100_R31) 1978; 2
Miles ( key 2019041113575174100_R28) 1983; 24
Ridker ( key 2019041113575174100_R8) 2003; 107
Sutinen ( key 2019041113575174100_R22) 2002; 16
Omagari ( key 2019041113575174100_R33) 2002; 17
Kerner ( key 2019041113575174100_R6) 2005; 25
Santoliquido ( key 2019041113575174100_R18) 2005; 9
Strang ( key 2019041113575174100_R39) 1998; 81
Thomsen ( key 2019041113575174100_R20) 1994; 12
Moitra ( key 2019041113575174100_R11) 1998; 12
Prati ( key 2019041113575174100_R34) 2002; 137
Yki-Jarvinen ( key 2019041113575174100_R7) 2003; 23
Mertens ( key 2019041113575174100_R9) 2006; 30
Kelley ( key 2019041113575174100_R16) 2003; 285
Agarwal ( key 2019041113575174100_R12) 2003; 14
Kadish ( key 2019041113575174100_R24) 1968; 14
Stenman ( key 2019041113575174100_R26) 1984; 297
Szczepaniak ( key 2019041113575174100_R29) 2005; 288
Marti ( key 2019041113575174100_R23) 1991; 45
Friedewald ( key 2019041113575174100_R27) 1972; 18
Adiels ( key 2019041113575174100_R5) 2006; 49
Stefan ( key 2019041113575174100_R14) 2005; 90
Ryysy ( key 2019041113575174100_R4) 2000; 49
Polonsky ( key 2019041113575174100_R41) 1984; 33
Alberti ( key 2019041113575174100_R42) 1998; 15
Westerbacka ( key 2019041113575174100_R13) 2004; 47
Bellentani ( key 2019041113575174100_R17) 2000; 132
Armitage ( key 2019041113575174100_R32) 1966; 30
Seppala-Lindroos ( key 2019041113575174100_R3) 2002; 87
Lukaski ( key 2019041113575174100_R21) 1985; 41
Pietilainen ( key 2019041113575174100_R19) 2005; 288
Tiikkainen ( key 2019041113575174100_R40) 2004; 53
Nielsen ( key 2019041113575174100_R30) 2004; 113
McKenzie ( key 2019041113575174100_R36) 2006; 65
Goto ( key 2019041113575174100_R38) 1995; 19
References_xml – volume: 49
  start-page: 749
  year: 2000
  ident: key 2019041113575174100_R4
  article-title: Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients.
  publication-title: Diabetes
  doi: 10.2337/diabetes.49.5.749
– volume: 132
  start-page: 112
  year: 2000
  ident: key 2019041113575174100_R17
  article-title: Prevalence of and risk factors for hepatic steatosis in northern Italy.
  publication-title: Ann Intern Med
  doi: 10.7326/0003-4819-132-2-200001180-00004
– volume: 25
  start-page: 193
  year: 2005
  ident: key 2019041113575174100_R6
  article-title: Association between elevated liver enzymes and C-reactive protein: possible hepatic contribution to systemic inflammation in the metabolic syndrome.
  publication-title: Arterioscler Thromb Vasc Biol
  doi: 10.1161/01.ATV.0000148324.63685.6a
– volume: 14
  start-page: 214
  year: 2003
  ident: key 2019041113575174100_R12
  article-title: Congenital generalized lipodystrophy: significance of triglyceride biosynthetic pathways.
  publication-title: Trends Endocrinol Metab
  doi: 10.1016/S1043-2760(03)00078-X
– volume: 26
  start-page: 22
  year: 1977
  ident: key 2019041113575174100_R25
  article-title: Determination of free and total insulin and C-peptide in insulin-treated diabetics.
  publication-title: Diabetes
  doi: 10.2337/diab.26.1.22
– volume: 49
  start-page: 755
  year: 2006
  ident: key 2019041113575174100_R5
  article-title: Overproduction of large VLDL particles is driven by increased liver fat content in man.
  publication-title: Diabetologia
  doi: 10.1007/s00125-005-0125-z
– volume: 297
  start-page: 327
  year: 1984
  ident: key 2019041113575174100_R26
  article-title: Rapid chromatographic quantitation of glycosylated haemoglobins.
  publication-title: J Chromatogr
  doi: 10.1016/S0021-9673(01)89052-X
– year: 1971
  ident: key 2019041113575174100_R35
– volume: 41
  start-page: 810
  year: 1985
  ident: key 2019041113575174100_R21
  article-title: Assessment of fat-free mass using bioelectrical impedance measurements of the human body.
  publication-title: Am J Clin Nutr
  doi: 10.1093/ajcn/41.4.810
– volume: 15
  start-page: 539
  year: 1998
  ident: key 2019041113575174100_R42
  article-title: Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation.
  publication-title: Diabet Med
  doi: 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S
– volume: 12
  start-page: 3168
  year: 1998
  ident: key 2019041113575174100_R11
  article-title: Life without white fat: a transgenic mouse.
  publication-title: Genes Dev
  doi: 10.1101/gad.12.20.3168
– volume: 285
  start-page: E906
  year: 2003
  ident: key 2019041113575174100_R16
  article-title: Fatty liver in type 2 diabetes mellitus: relation to regional adiposity, fatty acids, and insulin resistance
  publication-title: Am J Physiol Endocrinol Metab
  doi: 10.1152/ajpendo.00117.2003
– volume: 17
  start-page: 1098
  year: 2002
  ident: key 2019041113575174100_R33
  article-title: Fatty liver in non-alcoholic non-overweight Japanese adults: Incidence and clinical characteristics.
  publication-title: J Gastroenterol Hepatol
  doi: 10.1046/j.1440-1746.2002.02846.x
– volume: 19
  start-page: 841
  year: 1995
  ident: key 2019041113575174100_R38
  article-title: The influence of fatty liver on insulin clearance and insulin resistance in non-diabetic Japanese subjects.
  publication-title: Int J Obes Relat Metab Disord
– volume: 30
  start-page: 1308
  year: 2006
  ident: key 2019041113575174100_R9
  article-title: Among inflammation and coagulation markers, PAI-1 is a true component of the metabolic syndrome.
  publication-title: Int J Obes (Lond)
  doi: 10.1038/sj.ijo.0803189
– volume: 107
  start-page: 391
  year: 2003
  ident: key 2019041113575174100_R8
  article-title: C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: An 8-year follow-up of 14,719 initially healthy American women.
  publication-title: Circulation
  doi: 10.1161/01.CIR.0000055014.62083.05
– volume: 288
  start-page: E768
  year: 2005
  ident: key 2019041113575174100_R19
  article-title: Acquired obesity is associated with increased liver fat, intra-abdominal fat, and insulin resistance in young adult monozygotic twins
  publication-title: Am J Physiol Endocrinol Metab
  doi: 10.1152/ajpendo.00381.2004
– volume: 81
  start-page: 740
  year: 1998
  ident: key 2019041113575174100_R39
  article-title: Relationship of triglyceride accumulation to insulin clearance and hormonal responsiveness in bovine hepatocytes.
  publication-title: J Dairy Sci
  doi: 10.3168/jds.S0022-0302(98)75630-9
– volume: 53
  start-page: 2169
  year: 2004
  ident: key 2019041113575174100_R40
  article-title: Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes.
  publication-title: Diabetes
  doi: 10.2337/diabetes.53.8.2169
– volume: 37
  start-page: 347
  year: 2005
  ident: key 2019041113575174100_R2
  article-title: Fat in the liver and insulin resistance.
  publication-title: Ann Med
  doi: 10.1080/07853890510037383
– volume: 137
  start-page: 1
  year: 2002
  ident: key 2019041113575174100_R34
  article-title: Updated definitions of healthy ranges for serum alanine aminotransferase levels.
  publication-title: Ann Intern Med
  doi: 10.7326/0003-4819-137-1-200207020-00006
– volume: 65
  start-page: 40
  year: 2006
  ident: key 2019041113575174100_R36
  article-title: Effects of HRT on liver enzyme levels in women with type 2 diabetes: a randomized placebo-controlled trial.
  publication-title: Clin Endocrinol (Oxf)
  doi: 10.1111/j.1365-2265.2006.02543.x
– volume: 288
  start-page: E462
  year: 2005
  ident: key 2019041113575174100_R29
  article-title: Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population
  publication-title: Am J Physiol Endocrinol Metab
  doi: 10.1152/ajpendo.00064.2004
– volume: 2
  start-page: 892
  year: 1978
  ident: key 2019041113575174100_R31
  article-title: Relation between H.D.L.-cholesterol levels and triglyceride metabolism
  publication-title: Lancet
  doi: 10.1016/S0140-6736(78)91595-7
– volume: 16
  start-page: 2183
  year: 2002
  ident: key 2019041113575174100_R22
  article-title: Increased fat accumulation in the liver in HIV-infected patients with antiretroviral therapy-associated lipodystrophy.
  publication-title: AIDS
  doi: 10.1097/00002030-200211080-00011
– volume: 30
  start-page: 337
  year: 1966
  ident: key 2019041113575174100_R32
  article-title: The variability of measurements of casual blood pressure. II. Survey experience.
  publication-title: Clin Sci
– volume: 23
  start-page: 688
  year: 2003
  ident: key 2019041113575174100_R7
  article-title: Regulation of plasma PAI-1 concentrations in HAART-associated lipodystrophy during rosiglitazone therapy.
  publication-title: Arterioscler Thromb Vasc Biol
  doi: 10.1161/01.ATV.0000062885.61917.A5
– volume: 45
  start-page: 131
  year: 1991
  ident: key 2019041113575174100_R23
  article-title: Body fat distribution in the Finnish population: environmental determinants and predictive power for cardiovascular risk factor levels.
  publication-title: J Epidemiol Community Health
  doi: 10.1136/jech.45.2.131
– volume: 90
  start-page: 4238
  year: 2005
  ident: key 2019041113575174100_R14
  article-title: Liver fat and insulin resistance are independently associated with the −514C>T polymorphism of the hepatic lipase gene.
  publication-title: J Clin Endocrinol Metab
  doi: 10.1210/jc.2004-2479
– volume: 10
  start-page: 859
  year: 2002
  ident: key 2019041113575174100_R10
  article-title: Liver-fat accumulation and insulin resistance in obese women with previous gestational diabetes.
  publication-title: Obes Res
  doi: 10.1038/oby.2002.118
– volume: 9
  start-page: 269
  year: 2005
  ident: key 2019041113575174100_R18
  article-title: Hepatic steatosis and vascular disease.
  publication-title: Eur Rev Med Pharmacol Sci
– volume: 24
  start-page: 96
  year: 1983
  ident: key 2019041113575174100_R28
  article-title: A microfluorometric method for the determination of free fatty acids in plasma.
  publication-title: J Lipid Res
  doi: 10.1016/S0022-2275(20)38029-9
– volume: 12
  start-page: 487
  year: 1994
  ident: key 2019041113575174100_R20
  article-title: Quantification of liver fat using magnetic resonance spectroscopy.
  publication-title: Magn Reson Imaging
  doi: 10.1016/0730-725X(94)92543-7
– volume: 39
  start-page: 754
  year: 2004
  ident: key 2019041113575174100_R37
  article-title: Body fat distribution, relative weight, and liver enzyme levels: a population-based study.
  publication-title: Hepatology
  doi: 10.1002/hep.20149
– volume: 143
  start-page: 722
  year: 2005
  ident: key 2019041113575174100_R15
  article-title: The metabolic syndrome as a predictor of nonalcoholic fatty liver disease.
  publication-title: Ann Intern Med
  doi: 10.7326/0003-4819-143-10-200511150-00009
– volume: 33
  start-page: 486
  year: 1984
  ident: key 2019041113575174100_R41
  article-title: C-peptide as a measure of the secretion and hepatic extraction of insulin. Pitfalls and limitations.
  publication-title: Diabetes
  doi: 10.2337/diab.33.5.486
– start-page: 1059
  volume-title: Lancet
  year: 2005
  ident: key 2019041113575174100_R1
  article-title: The metabolic syndrome—a new worldwide definition.
– volume: 87
  start-page: 3023
  year: 2002
  ident: key 2019041113575174100_R3
  article-title: Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men.
  publication-title: J Clin Endocrinol Metab
  doi: 10.1210/jcem.87.7.8638
– volume: 113
  start-page: 1582
  year: 2004
  ident: key 2019041113575174100_R30
  article-title: Splanchnic lipolysis in human obesity.
  publication-title: J Clin Invest
  doi: 10.1172/JCI21047
– volume: 47
  start-page: 1360
  year: 2004
  ident: key 2019041113575174100_R13
  article-title: Women and men have similar amounts of liver and intra-abdominal fat, despite more subcutaneous fat in women: implications for sex differences in markers of cardiovascular risk.
  publication-title: Diabetologia
  doi: 10.1007/s00125-004-1460-1
– volume: 18
  start-page: 499
  year: 1972
  ident: key 2019041113575174100_R27
  article-title: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.
  publication-title: Clin Chem
  doi: 10.1093/clinchem/18.6.499
– volume: 14
  start-page: 116
  year: 1968
  ident: key 2019041113575174100_R24
  article-title: A new and rapid method for the determination of glucose by measurement of rate of oxygen consumption.
  publication-title: Clin Chem
  doi: 10.1093/clinchem/14.2.116
SSID ssj0014453
Score 2.4358723
Snippet Background: The liver, once fatty, overproduces components of the metabolic syndrome, such as glucose and lipids. The amount of liver fat in subjects with and...
The liver, once fatty, overproduces components of the metabolic syndrome, such as glucose and lipids. The amount of liver fat in subjects with and without the...
SourceID proquest
pubmed
pascalfrancis
crossref
oup
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 3490
SubjectTerms Abdominal Fat - anatomy & histology
Adult
Aged
Alanine transaminase
Aspartate aminotransferase
Biological and medical sciences
Body Composition
Body mass index
C-Peptide - blood
Diabetes mellitus
Endocrinopathies
Feeding. Feeding behavior
Female
Fundamental and applied biological sciences. Psychology
Gender
Humans
Insulin
Insulin resistance
Lipid metabolism
Lipids - analysis
Liver
Liver - chemistry
Liver - enzymology
Magnetic resonance imaging
Magnetic resonance spectroscopy
Male
Medical sciences
Metabolic syndrome
Metabolic Syndrome - blood
Metabolic Syndrome - diagnostic imaging
Metabolic Syndrome - etiology
Middle Aged
Peptides
Radiography
Sex Characteristics
Vertebrates: anatomy and physiology, studies on body, several organs or systems
Vertebrates: endocrinology
Women
Title Liver Fat in the Metabolic Syndrome
URI https://www.ncbi.nlm.nih.gov/pubmed/17595248
https://www.proquest.com/docview/3164416402
https://www.proquest.com/docview/68246508
Volume 92
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVBFR
  databaseName: Free Medical Journals
  customDbUrl:
  eissn: 1945-7197
  dateEnd: 20241003
  omitProxy: true
  ssIdentifier: ssj0014453
  issn: 0021-972X
  databaseCode: DIK
  dateStart: 19970101
  isFulltext: true
  titleUrlDefault: http://www.freemedicaljournals.com
  providerName: Flying Publisher
– providerCode: PRVFQY
  databaseName: Geneva Foundation for Medical Education and Research Open Access Journals
  customDbUrl:
  eissn: 1945-7197
  dateEnd: 20241003
  omitProxy: true
  ssIdentifier: ssj0014453
  issn: 0021-972X
  databaseCode: GX1
  dateStart: 19960101
  isFulltext: true
  titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php
  providerName: Geneva Foundation for Medical Education and Research
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbKkBASQtwpjBEJeJqCcnHs5LFMZS1rV2l0Ut8i23EkGKQTTV_49ZwTO06GWnF5idLEdSKfk8_ns8-FkLeAcDosFPeZDkNMqk19mQjmgy0Q6pTBnN7UBpyfs8kl_bRKVoPBth9dUsv36ufOuJL_kSpcA7lilOw_SNZ1ChfgHOQLR5AwHP9KxjN0qjguRd16K37XNQgV81bvykSAKtHLFOGCInVVrAE8qi4dU9uPTS-IgLxYXizOx8YpoKo6MB9_BoP4w-jkbGSCPK6uOoo_vjidLGbzzoPbAfF0vJzOcJM-pVPb6xmun9hYiXYZgjs_K7s2Zt9Ut96mfdBFLxDeVE13oJtFPeXKeggaU1M-1M7G8JPvRHqgqoj0JgulDzgUdTNau4v_20Tn3A_BCMIQ9-AWuR1xxrDwxenKeQYBxbTJS-1723gJDHbqP--GJWOiI-9diw3IrTQ1UfaTlsZ4WT4g9y3r8EZGhR6Sga4ekTtz61fxmLxpNMkDTfK-VB5okuc0yWs16Qm5_Dhenkx8Wz7DVzHPap8HlLEyCFQqMhqoBD5LmgnBCgBeLURcRDKNJGM6A9pdUA3EXpZgbwrKJPDqMn5KDqp1pZ8TTwValFIzypmiOisknMkgAqpf8FCpdEiO26HIlc0tjyVOvuXIMWHg8q8KC57yHAduSN651tcmp8qedh6M6r4mvmlydGPIu8ZWxENy2Mogt1_YJo9DZAGMBvD_1-424CpulolKr7ebnKURRfYyJM-M5LqueZIlEU1f_OnZL8nd7ks5JAf1j61-BSZsLY8ahfsFQhyT0Q
linkProvider Geneva Foundation for Medical Education and Research
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Liver+fat+in+the+metabolic+syndrome&rft.jtitle=The+journal+of+clinical+endocrinology+and+metabolism&rft.au=KOTRONEN%2C+Anna&rft.au=WESTERBACKA%2C+Jukka&rft.au=BERGHOLM%2C+Robert&rft.au=PIETIL%C3%84INEN%2C+Kirsi+H&rft.date=2007-09-01&rft.pub=Endocrine+Society&rft.issn=0021-972X&rft.volume=92&rft.issue=9&rft.spage=3490&rft.epage=3497&rft_id=info:doi/10.1210%2Fjc.2007-0482&rft.externalDBID=n%2Fa&rft.externalDocID=19081800
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0021-972X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0021-972X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0021-972X&client=summon